Upstream Bio has dosed the first subject in the Phase II trial of verekitug in individuals with chronic obstructive pulmonary disease (COPD).

Phase 2 trial launched for verekitug in COPD, expanding treatment indications for severe respiratory conditions. Top data expected in 2026.

Broadens global development program for verekitug into third indication, strengthening pipeline across severe respiratory diseases including chronic rhinosinusitis with nasal polyps (CRSwNP), severe ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

As of late Friday morning the air quality levels around Montezuma County have reached moderate levels, according to the U.S.

A recent national study revealed ongoing symptom burden and communication gaps in COPD care, and provided physicians with ...

A comprehensive meta-analysis of over 4.3 million adults shows e-cigarette use is associated with significantly higher odds ...

Dhaka, the overcrowded capital city of Bangladesh, has ranked 39th on the list of cities with the worst air quality with an ...

The CRYSTAL trial is the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating patients with moderate COPD from their current treatments.

Dhaka, the overcrowded capital city of Bangladesh, has ranked ninth on the list of cities with the worst air quality, with an ...

After a few days of jubilant fireworks launching, Columbus' air quality is taking a hit, causing the Mid-Ohio Planning ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...